Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for...
SAN ANTONIO — Promising data don’t always equal a stock pop. Viking Therapeutics presented what analysts thought were compelling data on an oral GLP-1/GIP dual agonist on Sunday evening, but the market...
View ArticleSana narrows focus again to zero in on diabetes and autoimmune disease
Sana Biotechnology is pruning its pipeline and headcount for the second time in around a year to stretch its cash and support key data readouts over the next 12 to 18 months. The change in ...
View ArticleNektar divests manufacturing site and reagent arm for $90M
Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is expected to...
View ArticleVertex makes money from sickle cell therapy Casgevy
Vertex said it made $2 million in revenue from the first patient who received its sickle cell therapy Casgevy. The commercial launches of Casgevy and bluebird bio’s Lyfgenia have been closely watched...
View ArticlePrognomiQ raises $34M for lung cancer test
PrognomiQ has raised an additional $34 million in funding as the company prepares to release its blood-based protein test for lung cancer. The company is part of the growing rush to mine ...
View Article#ASH24: Beam discloses first clinical data on base-edited sickle cell...
Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment for sickle cell disease. As of July 2, six people with severe sickle cell...
View ArticleSyndax inks a $350M royalty deal; FDA pushes back decision on Organon’s...
Plus, news about Merus, Supernus and Verrica: Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease treatment....
View Article#ASH24: Sanofi reveals positive Phase 3 data for BTK inhibitor from $3.7B...
Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to zero patients in the placebo arm, the...
View Article#ASH24: Gilead and Arcellx spotlight safety of multiple myeloma cell therapy,...
Gilead and Arcellx’s early trial data on their multiple myeloma cell therapy show that patients saw no cases of certain delayed neurotoxicities, which are associated with Johnson & Johnson and...
View Article#ASH24: J&J's Darzalex hits primary endpoint in Phase 3 early-stage multiple...
Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with high-risk smoldering multiple myeloma, a precursor to active multiple...
View ArticleZealand details Phase 1 obesity data for amylin drug as it plans next steps
SAN ANTONIO — Zealand Pharma, hoping to create the next "foundational" therapy for obesity, detailed more Phase 1 data on its amylin analog that was the backbone of a $1 billion raise this summer....
View Article#ASH24: Novo Nordisk takes Forma’s sickle cell treatment into Phase 3
Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The Danish pharma company, known for its diabetes and obesity treatments, plans...
View ArticleCatalent touts customer confidence ahead of Novo deal, but misses revenue...
Catalent reported a slight revenue upswing during its latest quarterly results, which CEO Alessandro Maselli attributed to "customers' continued confidence” in the CDMO. Yet the manufacturer missed...
View ArticleCerebral to pay nearly $3.7M over controlled substance prescribing practices
Troubled mental health startup Cerebral has agreed to pay nearly $3.7 million in connection with its efforts to encourage unauthorized prescriptions of ADHD medications and other controlled substances...
View ArticleOne biotech is looking to lessen antipsychotic-induced weight gain, despite...
Response Pharmaceuticals believes its experimental drug can lessen the persistent weight gain associated with antipsychotics. In a new pilot study, the company assessed RDX-002 in 20 healthy people....
View Article‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs
SAN ANTONIO — It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's next frontier: staving off the losses in muscle or lean...
View ArticleAcadia lands $150M sale of rare pediatric PRV
Acadia Pharmaceuticals has sold its priority review voucher for $150 million, the company said Tuesday, but did not disclose the buyer. The FDA granted Acadia the rare pediatric PRV in March ...
View ArticleNovo unveils new cardiometabolic data as it reports solid third-quarter profits
Novo Nordisk disclosed several key updates from its cardiometabolic and hematology pipelines Wednesday as the drugmaker revealed its third-quarter profits edged out expectations. First up, the Danish...
View ArticleNew Trump era could be a boon for biopharma M&A, dealmaking
As former President Donald Trump returns to power — the Associated Press projected his presidential victory Wednesday morning — the biopharma industry may see the door open wider for more dealmaking,...
View Article